A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)

Astellas Pharma Inc1,108 enrolled

Overview

The study will examine which dose of YM178 is best in terms of efficacy, safety and tolerability compared to placebo and compared to tolterodine, a marketed product.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

1,108

Conditions

Overactive Bladder

Interventions

YM178DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients over 18 years suffering from overactive bladder (OAB) for more than 3 months Exclusion Criteria: * Pregnant and breastfeeding women * Any medical condition or need for co-medication which interferes with the drug under investigation (YM178) or the comparator (tolterodine)

Locations (84)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

3 Sites

Antwerp, Belgium

2 Sites

Brussels, Belgium

Unnamed facility

Ghent, Belgium

Unnamed facility

Leuven, Belgium

Unnamed facility

Liège, Belgium

Unnamed facility

Brno, Czechia

Unnamed facility

Mělník, Czechia

Unnamed facility

Ostrava, Czechia

3 Sites

Prague, Czechia

Unnamed facility

Ústí nad Labem, Czechia

...and 74 more locations